NICE, France--(BUSINESS WIRE)--June 14, 2006--In coordination with Cardiostim 2006, the 15th World Congress in Cardiac Electrophysiology and Cardiac Techniques, Medtronic, Inc., (NYSE:MDT - News) today announced European approval and market availability of the Concerto(TM)/Virtuoso(TM) line of implantable devices, which includes the Concerto cardiac resynchronisation therapy-defibrillator (CRT-D) and Virtuoso single- and dual-chamber implantable cardioverter-defibrillators (ICDs). These are Medtronic’s first cardiac rhythm disease management devices with wireless telemetry, enabling communication remotely between the implanted device and programmers in a clinician’s office and at implant, or between the device and a patient home monitor.
